Lansen Pharmaceutical Holdings Limited, an investment holding company, develops, produces, and sells specialty pharmaceuticals for use in the field of rheumatology and dermatology in the People’s Republic of China and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$1.48|
|52 Week High||HK$0.71|
|52 Week Low||HK$4.15|
|1 Month Change||-33.63%|
|3 Month Change||-42.19%|
|1 Year Change||94.74%|
|3 Year Change||43.69%|
|5 Year Change||-22.51%|
|Change since IPO||-67.54%|
Recent News & Updates
Is Lansen Pharmaceutical Holdings (HKG:503) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
|503||HK Pharmaceuticals||HK Market|
Return vs Industry: 503 exceeded the Hong Kong Pharmaceuticals industry which returned -12% over the past year.
Return vs Market: 503 exceeded the Hong Kong Market which returned 9.1% over the past year.
Stable Share Price: 503 is more volatile than 90% of Hong Kong stocks over the past 3 months, typically moving +/- 25% a week.
Volatility Over Time: 503's weekly volatility has increased from 15% to 25% over the past year.
About the Company
Lansen Pharmaceutical Holdings Limited, an investment holding company, develops, produces, and sells specialty pharmaceuticals for use in the field of rheumatology and dermatology in the People’s Republic of China and internationally. It operates through Pharmaceuticals, Cosmetics Products, and Healthcare Products segments. The company offers specialist medicines and Chinese medicine generic drugs; cosmetic products; and plant extracts and healthcare products.
Lansen Pharmaceutical Holdings Fundamentals Summary
|503 fundamental statistics|
Is 503 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|503 income statement (TTM)|
|Cost of Revenue||US$18.70m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.018|
|Net Profit Margin||-13.13%|
How did 503 perform over the long term?See historical performance and comparison
Is Lansen Pharmaceutical Holdings undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 503 (HK$1.48) is trading below our estimate of fair value (HK$8.64)
Significantly Below Fair Value: 503 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 503 is unprofitable, so we can't compare its PE Ratio to the Hong Kong Pharmaceuticals industry average.
PE vs Market: 503 is unprofitable, so we can't compare its PE Ratio to the Hong Kong market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 503's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 503 is good value based on its PB Ratio (0.4x) compared to the HK Pharmaceuticals industry average (1.1x).
How is Lansen Pharmaceutical Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lansen Pharmaceutical Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Lansen Pharmaceutical Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 503 is currently unprofitable.
Growing Profit Margin: 503 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 503 is unprofitable, but has reduced losses over the past 5 years at a rate of 46.9% per year.
Accelerating Growth: Unable to compare 503's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 503 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.8%).
Return on Equity
High ROE: 503 has a negative Return on Equity (-3.38%), as it is currently unprofitable.
How is Lansen Pharmaceutical Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: 503's short term assets ($191.5M) exceed its short term liabilities ($52.0M).
Long Term Liabilities: 503's short term assets ($191.5M) exceed its long term liabilities ($2.5M).
Debt to Equity History and Analysis
Debt Level: 503's debt to equity ratio (14.7%) is considered satisfactory.
Reducing Debt: 503's debt to equity ratio has reduced from 103.3% to 14.7% over the past 5 years.
Debt Coverage: 503's debt is well covered by operating cash flow (54.9%).
Interest Coverage: 503's interest payments on its debt are well covered by EBIT (37.7x coverage).
What is Lansen Pharmaceutical Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 503's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 503's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 503's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 503's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: 503 is not paying a notable dividend for the Hong Kong market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 503's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Li Chen (59 yo)
Mr. Li Chen has been Chief Executive Officer and Executive Managing Director of Lansen Pharmaceutical Holdings Ltd since March 1, 2018. He has been General Manager in Alfa Wassermann China since July 2014....
CEO Compensation Analysis
Compensation vs Market: Li's total compensation ($USD624.00K) is above average for companies of similar size in the Hong Kong market ($USD229.36K).
Compensation vs Earnings: Li's compensation has been consistent with company performance over the past year.
Experienced Board: 503's board of directors are considered experienced (8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Lansen Pharmaceutical Holdings Limited's employee growth, exchange listings and data sources
- Name: Lansen Pharmaceutical Holdings Limited
- Ticker: 503
- Exchange: SEHK
- Founded: 2001
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$552.813m
- Shares outstanding: 373.52m
- Website: https://www.lansen.com.cn
Number of Employees
- Lansen Pharmaceutical Holdings Limited
- 228 Xinfeng Road
- Gaoqiao Industrial Park
- Zhejiang Province
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/27 15:44|
|End of Day Share Price||2021/09/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.